Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct 15;47(8):1102-4.
doi: 10.1086/592115.

Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status

Richard D Moore  1 , Kelly A Gebo, Gregory M Lucas, Jeanne C Keruly
Affiliations

Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status

Richard D Moore et al. Clin Infect Dis. .

Abstract

The rate of comorbidities not related to human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) among HIV-infected patients may be higher than expected. We assessed the incidence of comorbidities not related to HIV infection or AIDS by CD4 cell count and highly active antiretroviral therapy (HAART) use status in an HIV clinical practice. A total of 2824 patients contributed 9172 person-years of longitudinal data during the period 1997-2006. Among patients with a CD4 cell count <350 cells/mm(3), receipt of HAART was associated with a significantly decreased incidence of comorbidities not related to HIV infection or AIDS.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. R.D.M. has been a consultant for Bristol-Myers Squibb and has received research funding from Merck, Pfizer, and Gilead. All other authors: no conflicts.

References

    1. El-Sadr W, Neaton J. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. N Engl J Med. 2006;355:2283–96. - PubMed
    1. Palella F, Baker RK, Moorman AC, et al. HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
    1. Friis-Møller N, Reiss P, Sabin CA, et al. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35. - PubMed
    1. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40:609–16. - PubMed
    1. Braithwaite RS, Justice AC, Chang CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118:890–8. - PubMed

Publication types